Abstract: The present invention provides a method for preparing a tablet for the vaginal administration of progesterone for systemic use. The method comprises first mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, drying the wetted, micronized progesterone; mixing the dry micronized progesterone with other pharmaceutically acceptable excipients or diluents; and; forming a tablet by direct compaction of the dry micronized progesterone. Tablets prepared by this method are also provided.

Abstract: The present invention provides a method for preparing a tablet for the vaginal administration of progesterone for systemic use. The method comprises first mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, drying the wetted, micronized progesterone; mixing the dry micronized progesterone with other pharmaceutically acceptable excipients or diluents; and; forming a tablet by direct compaction of the dry micronized progesterone. Tablets prepared by this method are also provided.

Abstract: An apparatus for delivery of a fluid is disclosed. The apparatus includes a syringe pump with a plunger, an electronic control element which releases at least one electric charge at predetermined time intervals, a shape memory element with a contractible length decreasing from an uncharged length to a charged length, and a driving mechanism connected to both the shape memory element and the plunger so that the change in length of the shape memory element causes the driving mechanism to provide an activating force to move the plunger and force the expulsion of the fluid from the syringe pump's chamber. As the apparatus according to the present invention can be manufactured as a disposable unit, the problems associated with reusable syringe pumps are avoided.

Abstract: Preparation of renin inhibitors based on the structure of natural renin substrate at residues 6 to 13 from the amino terminal thereof, the inhibitors being polypeptide analogues having in particular an isosteric non-peptide link corresponding to the 10, 11 peptide link of the substrate, and preparation of dipeptide analogues.

Abstract: 1-Deamino-8-D-arginine vasopressin is useful in the prophylaxis and treatment of sickle cell disease.